Kling Biotherapeutics

Ownership

Private

Therapeutic Areas

OncologyInfectious Diseases

Stage

Phase 1

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Antibody-based therapeuticsMonoclonal antibodies

Kling Biotherapeutics General Information

Currently testing KBA1412, a first-in-class CD9 antibody, in a Phase 1 clinical trial for advanced malignant solid neoplasms

Contact Information

Website

https://www.klingbio.com/

Primary Industry

Biotech

Corporate Office

Amsterdam,
Netherlands

Drug Pipeline

KBA1412

Phase 1

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Kling Biotherapeutics's pipeline data

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Kling Biotherapeutics Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Kling Biotherapeutics's complete valuation and funding history, request access »

Kling Biotherapeutics Financial Metrics